Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Recent & Breaking News (NDAQ:AXSM)

UPCOMING AXSM DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors with Substantial Losses to Contact the Firm!

Accesswire December 3, 2023

UPCOMING AXSM DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors with Substantial Losses to Contact the Firm!

Accesswire December 1, 2023

AXSM SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors with Losses to Lead Class Action Lawsuit!

Accesswire November 30, 2023

AXSM SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors with Losses to Lead Class Action Lawsuit!

Accesswire November 29, 2023

AXSM SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors with Losses to Lead Class Action Lawsuit!

Accesswire November 28, 2023

AXSM SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors with Losses to Lead Class Action Lawsuit!

Accesswire November 27, 2023

AXSM FINAL DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

PR Newswire November 26, 2023

AXSM SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors with Losses to Lead Class Action Lawsuit!

Accesswire November 26, 2023

AXSM FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

TheNewsWire November 25, 2023

AXSM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Axsome Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Accesswire November 24, 2023

AXSM FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

Newsfile November 23, 2023

AXSM FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

Newsfile November 22, 2023

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

GlobeNewswire November 22, 2023

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

TheNewsWire November 22, 2023

Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

GlobeNewswire November 21, 2023

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

Newsfile November 20, 2023

ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

PR Newswire November 20, 2023

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

TheNewsWire November 18, 2023

Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers - AXSM

Business Wire November 16, 2023

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 6, 2023